Data from multiple sources - Curated by Toby Galbraith - Last updated 04 January 2017

Latest news articles

Added 6 months ago Drug news

UK NICE U-turn now recommends Imlygic (talimogene laherparepvec) for unresectable, regionally or distantly metastatic (Stage IIIB, IIIC or IVM1a) melanoma- Amgen

NICE has issued final guidance overturning its earlier recommendation, and now endorsing Imlygic (talimogene laherparepvec), from Amgen, as an option...

Added 7 months ago Drug news

Study of Chemosat (melphalan for injection) shows survival benefit in metastatic uveal melanoma patients- Delcath Systems

Delcath Systems has announced that data from a large single hospital experience of Chemosat (melphalan for injection) conducted at Southampton...

Added 8 months ago Drug news

UK NICE recommends use of Opdivo + Yervoy (nivolumab + ipilimumab) for advanced (unresectable or metastatic) melanoma - BMS

UK's NICE has recommended that the combination of Opdivo + Yervoy (nivolumab + ipilimumab), from BMS, for the treatment of...

View all news articles

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

Visit Chronic Lymphocytic Leukaemia (CLL)

Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more

Visit Psoriasis

Guidelines

Melanoma: assessment and management

This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults....

Added 1 year ago

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cutaneous melanoma is the most common type of melanoma, and UV exposure is one of the main risk factors. The...

Added 1 year ago

View all guidelines

Journal articles

Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib.

The BRAF inhibitor vemurafenib is an effective drug in patients with BRAF mutant metastatic melanoma, but resistance occurs after a...

Added 10 months ago

View all journal articles

CME

Case Consults: Changing Paradigms in the Age of Biologics

Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
FREE

Treatment Optimisation in Chronic Lymphocytic Leukaemia

Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
FREE
View all CME